NBTX — Nanobiotix S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1760854 ·
Last close
$33.31
Market Cap
$1.69B
52W High
$57.14
52W Low
$14.78
ADV30
160,157
Next earnings
2026-09-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 67,760,000 | 52,750,000 | 152,243,000 |
| Jun 2025 | — | — | — | — | 45,174,000 | 28,818,000 | 114,126,000 |
| Dec 2024 | — | — | — | — | 67,418,000 | 49,737,000 | 133,121,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-23,961,000
Inventory
—
Receivables
$7,680,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$32,593,000
EBITDA
$-10,489,000
Free Cash Flow
$-7,894,125
Enterprise Value
$1,833,406,976
Total Cash
$52,750,000
Total Debt
$95,319,000
Shares Out
50,811,344
Trailing EPS
$-0.58
Book Value
$-2.02
ROE
—
ROA
-10.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 29,643,000 | -10,818,000 | -23,961,000 | 67,760,000 | 152,243,000 | -84,483,000 | -33,422,000 |
| Dec 2024 | -11,610,000 | -68,392,000 | -68,132,000 | 67,418,000 | 133,121,000 | -65,703,000 | -19,551,000 |
| Dec 2023 | 30,058,000 | -26,778,000 | -39,700,000 | 93,897,000 | 95,741,000 | -1,844,000 | -12,476,000 |
| Dec 2022 | 0 | -46,703,000 | -57,041,000 | 59,769,000 | 86,814,000 | -27,045,000 | -37,103,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANIP | ANI PHARMACEUTICALS INC | $1.70B | $74.00 | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.66B | $9.10 | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.65B | $57.68 | — |
| GHRS | GH Research PLC | $1.64B | $23.84 | — |
| ZBIO | Zenas BioPharma, Inc. | $1.76B | $26.95 | — |
News headlines (Yahoo Finance, 1h cache)
Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?
2026-09-17 17:06 · Yahoo
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
2026-09-24 20:15 · Yahoo
Voting Rights and Shares Capital of the Company
2026-09-22 20:15 · Yahoo
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
2026-09-14 06:00 · Yahoo
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 20:15 · Yahoo
Nanobiotix (NBTX) Provides Update on Operational Progress
2026-06-22 12:47 · Yahoo
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
2026-06-02 20:30 · Yahoo
Nanobiotix Joins the Euronext Tech Leaders Index
2026-06-02 06:30 · Yahoo
Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally
2026-05-30 22:04 · Yahoo
NANOBIOTIX Announces Closing of Global Offering
2026-05-26 20:59 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.